National tuberculosis (TB) programs engage with international non-governmental organisations (INGOs), especially to provide TB care in complex settings where community involvement might be required. In Myanmar, however, there is limited data on how such INGO

Somalia, ravaged by conflict since 1991, has areas endemic for visceral leishmaniasis (VL), a deadly parasitic disease affecting the rural poor, internally displaced, and pastoralists. Very little is known about VL burden in Somalia, where

Despite emerging drug resistance in Cambodia, artemisinin-based combination therapy (ACT) is still the most efficacious therapy. ACT is available free of charge in the Cambodian public sector and at a subsidised rate in the private

The roll-out of medical male circumcision (MC) is progressing in Southern and Eastern Africa. Little is known about the effect of this roll-out on women. The objective of this study was to assess the knowledge

Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically last 20 months or more, require a patient to take a high number of pills, and often lead to unsatisfactory

Artemisinin-resistant Plasmodium falciparum malaria parasites are now present across much of mainland Southeast Asia, where ongoing surveys are measuring and mapping their spatial distribution. These efforts require substantial resources. Here we propose a generic ‘smart

During a cholera outbreak in May 2015, in Juba, South Sudan, the Ministry of Health, Doctors Without Borders/Médecins Sans Frontières (MSF) and partners engaged in the first field deployment of a single dose of oral cholera

Antibiotic stewardship program (ASP) implementation in humanitarian settings is a new endeavour – Doctors Without Borders/Médecins Sans Frontières (MSF) introduced an ASP within a hospital in Amman, Jordan, where patients from Iraq, Syria, and Yemen

In Afghanistan, Doctors Without Borders/Médecins Sans Frontières (MSF) provided specialised trauma care in Kunduz Trauma Centre (KTC), including physiotherapy. In this study, we describe the development of an adapted functional score for patient outcome monitoring

Today’s global market has multiple standards. Patients in low- and middle-income countries often receive poor-quality medicines. Despite increasing awareness about the issue and the launch of some initiatives, the divide in quality of pharmaceuticals between

Multidrug-resistant tuberculosis (MDR-TB) is a major threat to global TB control. MDR-TB treatment regimens typically have a high pill burden, last 20 months or more and often lead to unsatisfactory outcomes. A 9–11 month regimen

Collaborative clinical research that addresses the health needs of low and middle-income countries (LMICs) has become more frequent recently. Such research includes therapeutic and diagnostic trials for neglected tropical diseases (NTDs), and is often conducted